Glucagon/T3 corrects dyslipidemia, obesity, and hyperglycemia in DIO mice
Glucagon/T3 improves NASH and atherosclerosis in preclinical disease models
Precise delivery of T3 to the liver mediates benefits and spares cardiac toxicity
Hepatic T3 action counteracts the diabetogenic liability of glucagon